Bile acids in drug induced liver injury: Key players and surrogate markers

Clinics and Research in Hepatology and Gastroenterology

Volumn 40, Issue 3, 2016, Pages 257-266

  Schadt, Heiko S ^a   Wolf, Armin ^a   Pognan, Francois ^a   Chibout, Salah Dine ^a   Merz, Michael ^a   Kullak Ublick, Gerd A ^a,b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; BILE ACID; BOSENTAN; CYCLOSPORIN A; ORAL CONTRACEPTIVE AGENT; RIFAMPICIN; TROGLITAZONE; BIOLOGICAL MARKER;

BIOSYNTHESIS; CHOLESTASIS; CONJUGATION; DIARRHEA; DISEASE MARKER; DRUG INDUSTRY; ENTEROHEPATIC CIRCULATION; GENETIC DISORDER; HOMEOSTASIS; HUMAN; LIPID METABOLISM; NONALCOHOLIC FATTY LIVER; NONHUMAN; PHYSIOLOGY; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TOXIC HEPATITIS; BILE DUCT; CHEMICALLY INDUCED; CYTOLOGY; INTRAHEPATIC CHOLESTASIS; METABOLISM; PATHOPHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

BILE ACIDS AND SALTS; BILE DUCTS; BIOLOGICAL TRANSPORT; BIOMARKERS; CHEMICAL AND DRUG INDUCED LIVER INJURY; CHOLESTASIS, INTRAHEPATIC; ENTEROHEPATIC CIRCULATION; HOMEOSTASIS; HUMANS;

EID: 84957916532     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2015.12.017     Document Type: Review

References (101)

1. Standardization of definitions and criteria of causality assessment of adverse drug reactions. Drug-induced liver disorders: report of an international consensus meeting. Int J Clin Pharmacol Ther Toxicol 1990, 28(8):317-322.
2. Lasser K.E., Allen P.D., Woolhandler S.J., Himmelstein D.U., Wolfe S.M., Bor D.H. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002, 287(17):2215-2220.
3. Temple R.J., Himmel M.H. Safety of newly approved drugs: implications for prescribing. JAMA 2002, 287(17):2273-2275.
4. Fontana R.J., Seeff L.B., Andrade R.J., Bjornsson E., Day C.P., Serrano J., et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology 2010, 52(2):730-742.
5. Myant N.B., Mitropoulos K.A. Cholesterol 7 alpha-hydroxylase. J Lipid Res 1977, 18(2):135-153.
6. Chiang J.Y. Bile acid regulation of hepatic physiology: III. Bile acids and nuclear receptors. Am J Physiol Gastrointest Liver Physiol 2003, 284(3):G349-G356.
7. Thomas C., Pellicciari R., Pruzanski M., Auwerx J., Schoonjans K. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 2008, 7(8):678-693.
8. Russell D.W. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 2003, 72:137-174.
9. Russell D.W. Fifty years of advances in bile acid synthesis and metabolism. J Lipid Res 2009, 50 Suppl.:S120-S125.
10. Zhang Y., Klaassen C.D. Effects of feeding bile acids and a bile acid sequestrant on hepatic bile acid composition in mice. J Lipid Res 2010, 51(11):3230-3242.
11. Chiang J.Y. Bile acids: regulation of synthesis. J Lipid Res 2009, 50(10):1955-1966.
12. Falany C.N., Johnson M.R., Barnes S., Diasio R.B. Glycine and taurine conjugation of bile acids by a single enzyme. Molecular cloning and expression of human liver bile acid CoA:amino acid N-acyltransferase. J Biol Chem 1994, 269(30):19375-19379.
13. Sturman J.A., Messing J.M., Rossi S.S., Hofmann A.F., Neuringer M. Tissue taurine content, activity of taurine synthesis enzymes and conjugated bile acid composition of taurine-deprived and taurine-supplemented rhesus monkey infants at 6 and 12 mo of age. J Nutr 1991, 121(6):854-862.
14. Hofmann A.F., Hagey L.R. Key discoveries in bile acid chemistry and biology and their clinical applications: history of the last eight decades. J Lipid Res 2014, 55(8):1553-1595.
15. Matern S., Matern H., Farthmann E.H., Gerok W. Hepatic and extrahepatic glucuronidation of bile acids in man. Characterization of bile acid uridine 5'-diphosphate-glucuronosyltransferase in hepatic, renal, and intestinal microsomes. J Clin Invest 1984, 74(2):402-410.
16. Trottier J., Verreault M., Grepper S., Monte D., Belanger J., Kaeding J., et al. Human UDP-glucuronosyltransferase (UGT)1A3 enzyme conjugates chenodeoxycholic acid in the liver. Hepatology 2006, 44(5):1158-1170.
17. Takikawa H., Beppu T., Seyama Y. Urinary concentrations of bile acid glucuronides and sulfates in hepatobiliary diseases. Gastroenterol Jpn 1984, 19(2):104-109.
18. Radominska-Pyrek A., Zimniak P., Chari M., Golunski E., Lester R., St Pyrek J. Glucuronides of monohydroxylated bile acids: specificity of microsomal glucuronyltransferase for the glucuronidation site, C-3 configuration, and side chain length. J Lipid Res 1986, 27(1):89-101.
19. Shattuck K.E., Radominska-Pyrek A., Zimniak P., Adcock E.W., Lester R., St Pyrek J. Metabolism of 24-norlithocholic acid in the rat: formation of hydroxyl- and carboxyl-linked glucuronides and effect on bile flow. Hepatology 1986, 6(5):869-873.
20. Bock K.W. Roles of human UDP-glucuronosyltransferases in clearance and homeostasis of endogenous substrates, and functional implications. Biochem Pharmacol 2015, 96(2):77-82.
21. Dawson P.A., Lan T., Rao A. Bile acid transporters. J Lipid Res 2009, 50(12):2340-2357.
22. Kullak-Ublick G.A., Stieger B., Meier P.J. Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology 2004, 126(1):322-342.
23. Byrne J.A., Strautnieks S.S., Mieli-Vergani G., Higgins C.F., Linton K.J., Thompson R.J. The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology 2002, 123(5):1649-1658.
24. Noe J., Stieger B., Meier P.J. Functional expression of the canalicular bile salt export pump of human liver. Gastroenterology 2002, 123(5):1659-1666.
25. Meier P.J., Stieger B. Bile salt transporters. Annu Rev Physiol 2002, 64:635-661.
26. Lam P., Wang R., Ling V. Bile acid transport in sister of P-glycoprotein (ABCB11) knockout mice. Biochemistry 2005, 44(37):12598-12605.
27. Li N., Cui Z., Fang F., Lee J.Y., Ballatori N. Heterodimerization, trafficking and membrane topology of the two proteins, Ost alpha and Ost beta, that constitute the organic solute and steroid transporter. Biochem J 2007, 407(3):363-372.
28. Seward D.J., Koh A.S., Boyer J.L., Ballatori N. Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J Biol Chem 2003, 278(30):27473-27482.
29. Wang W., Seward D.J., Li L., Boyer J.L., Ballatori N. Expression cloning of two genes that together mediate organic solute and steroid transport in the liver of a marine vertebrate. Proc Natl Acad Sci U S A 2001, 98(16):9431-9436.
30. Lazaridis K.N., Pham L., Tietz P., Marinelli R.A., deGroen P.C., Levine S., et al. Rat cholangiocytes absorb bile acids at their apical domain via the ileal sodium-dependent bile acid transporter. J Clin Invest 1997, 100(11):2714-2721.
31. Beuers U., Hohenester S., de Buy Wenniger L.J., Kremer A.E., Jansen P.L., Elferink R.P. The biliary HCO(3)(-) umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies. Hepatology 2010, 52(4):1489-1496.
32. Salas J.T., Banales J.M., Sarvide S., Recalde S., Ferrer A., Uriarte I., et al. Ae2a,b-deficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis. Gastroenterology 2008, 134(5):1482-1493.
33. Poupon R., Ping C., Chretien Y., Corpechot C., Chazouilleres O., Simon T., et al. Genetic factors of susceptibility and of severity in primary biliary cirrhosis. J Hepatol 2008, 49(6):1038-1045.
34. Hohenester S., Wenniger LMdB, Paulusma C.C., van Vliet S.J., Jefferson D.M., Elferink R.P.O., et al. A biliary HCO3-umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes. Hepatology 2012, 55(1):173-183.
35. Maillette de Buy Wenniger L.J., Hohenester S., Maroni L., van Vliet S.J., Oude Elferink R.P., Beuers U. The cholangiocyte glycocalyx stabilizes the 'biliary HCO3 umbrella': an integrated line of defense against toxic bile acids. Dig Dis 2015, 33(3):397-407.
36. Eyssen H., De Pauw G., Stragier J., Verhulst A. Cooperative formation of omega-muricholic acid by intestinal microorganisms. Appl Environ Microbiol 1983, 45(1):141-147.
37. Dawson P.A. Role of the intestinal bile acid transporters in bile acid and drug disposition. Handb Exp Pharmacol 2011, (201):169-203.
38. Kuipers F., Bloks V.W., Groen A.K. Beyond intestinal soap - bile acids in metabolic control. Nat Rev Endocrinol 2014, 10(8):488-498.
39. Inagaki T., Choi M., Moschetta A., Peng L., Cummins C.L., McDonald J.G., et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005, 2(4):217-225.
40. Lin B.C., Wang M., Blackmore C., Desnoyers L.R. Liver-specific activities of FGF19 require Klotho beta. J Biol Chem 2007, 282(37):27277-27284.
41. Houten S.M., Watanabe M., Auwerx J. Endocrine functions of bile acids. EMBO J 2006, 25(7):1419-1425.
42. Kullak-Ublick G.A. ABC transporter regulation by bile acids: where PXR meets FXR. J Hepatol 2003, 39(4):628-630.
43. Landrier J.F., Eloranta J.J., Vavricka S.R., Kullak-Ublick G.A. The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-alpha and -beta genes. Am J Physiol Gastrointest Liver Physiol 2006, 290(3):G476-G485.
44. Goodwin B., Jones S.A., Price R.R., Watson M.A., McKee D.D., Moore L.B., et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 2000, 6(3):517-526.
45. Geier A., Wagner M., Dietrich C.G., Trauner M. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim Biophys Acta 2007, 3(1773):283-308.
46. Parks D.J., Blanchard S.G., Bledsoe R.K., Chandra G., Consler T.G., Kliewer S.A., et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999, 284(5418):1365-1368.
47. Makishima M., Okamoto A.Y., Repa J.J., Tu H., Learned R.M., Luk A., et al. Identification of a nuclear receptor for bile acids. Science 1999, 284(5418):1362-1365.
48. Hofmann A.F. The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med 1999, 159(22):2647-2658.
49. Roda A., Grigolo B., Pellicciari R., Natalini B. Structure-activity relationship studies on natural and synthetic bile acid analogs. Dig Dis Sci 1989, 34(12 Suppl.). 24S-35S.
50. Roda A., Minutello A., Angellotti M.A., Fini A. Bile acid structure-activity relationship: evaluation of bile acid lipophilicity using 1-octanol/water partition coefficient and reverse phase HPLC. J Lipid Res 1990, 31(8):1433-1443.
51. Rolo A.P., Oliveira P.J., Moreno A.J., Palmeira C.M. Bile acids affect liver mitochondrial bioenergetics: possible relevance for cholestasis therapy. Toxicol Sci 2000, 57(1):177-185.
52. Sharma R., Majer F., Peta V.K., Wang J., Keaveney R., Kelleher D., et al. Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A). Bioorg Med Chem 2010, 18(18):6886-6895.
53. Kunne C., de Graaff M., Duijst S., de Waart D.R., Oude Elferink R.P., Paulusma C.C. Hepatic cytochrome P450 deficiency in mouse models for intrahepatic cholestasis predispose to bile salt-induced cholestasis. Lab Invest 2014, 94(10):1103-1113.
54. Devkota S., Chang E.B. Interactions between diet, bile acid metabolism, gut microbiota, and inflammatory bowel diseases. Dig Dis 2015, 33(3):351-356.
55. Ridlon J.M., Kang D.J., Hylemon P.B., Bajaj J.S. Bile acids and the gut microbiome. Curr Opin Gastroenterol 2014, 30(3):332-338.
56. Degirolamo C., Rainaldi S., Bovenga F., Murzilli S., Moschetta A. Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-Fgf15 axis in mice. Cell Rep 2014, 7(1):12-18.
57. Yoshimoto S., Loo T.M., Atarashi K., Kanda H., Sato S., Oyadomari S., et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013, 499(7456):97-101.
58. Ridlon J.M., Kang D.J., Hylemon P.B., Bajaj J.S. Gut microbiota, cirrhosis, and alcohol regulate bile acid metabolism in the gut. Dig Dis 2015, 33(3):338-345.
59. Bajaj J.S., Cox I.J., Betrapally N.S., Heuman D.M., Schubert M.L., Ratneswaran M., et al. Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function. Am J Physiol Gastrointest Liver Physiol 2014, 307(10):G951-G957.
60. Stieger B., Fattinger K., Madon J., Kullak-Ublick G.A., Meier P.J. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 2000, 118(2):422-430.
61. Vallejo M., Briz O., Serrano M.A., Monte M.J., Marin J.J. Potential role of trans-inhibition of the bile salt export pump by progesterone metabolites in the etiopathogenesis of intrahepatic cholestasis of pregnancy. J Hepatol 2006, 44(6):1150-1157.
62. Abu-Hayyeh S., Martinez-Becerra P., Sheikh Abdul Kadir S.H., Selden C., Romero M.R., Rees M., et al. Inhibition of Na+-taurocholate Co-transporting polypeptide-mediated bile acid transport by cholestatic sulfated progesterone metabolites. J Biol Chem 2010, 285(22):16504-16512.
63. Abu-Hayyeh S., Papacleovoulou G., Lovgren-Sandblom A., Tahir M., Oduwole O., Jamaludin N.A., et al. Intrahepatic cholestasis of pregnancy levels of sulfated progesterone metabolites inhibit farnesoid X receptor resulting in a cholestatic phenotype. Hepatology 2013, 57(2):716-726.
64. Abu-Hayyeh S., Williamson C. Progesterone metabolites as farnesoid X receptor inhibitors. Dig Dis 2015, 33(3):300-306.
65. Kullak-Ublick G.A., Meier P.J. Mechanisms of cholestasis. Clin Liver Dis 2000, 4(2):357-385.
66. Reyes H., Sjovall J. Bile acids and progesterone metabolites in intrahepatic cholestasis of pregnancy. Ann Med 2000, 32(2):94-106.
67. Beuers U., Trauner M., Jansen P., Poupon R. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J Hepatol 2015, 62(1 Suppl.):S25-S37.
68. Pauli-Magnus C., Stieger B., Meier Y., Kullak-Ublick G.A., Meier P.J. Enterohepatic transport of bile salts and genetics of cholestasis. J Hepatol 2005, 43(2):342-357.
69. Chojkier M. Troglitazone and liver injury: in search of answers. Hepatology 2005, 41(2):237-246.
70. Watkins P.B. Insight into hepatotoxicity: the troglitazone experience. Hepatology 2005, 41(2):229-230.
71. Watkins P.B., Whitcomb R.W. Hepatic dysfunction associated with troglitazone. N Engl J Med 1998, 338(13):916-917.
72. Yamamoto Y., Yamazaki H., Ikeda T., Watanabe T., Iwabuchi H., Nakajima M., et al. Formation of a novel quinone epoxide metabolite of troglitazone with cytotoxicity to HepG2 cells. Drug Metab Dispos 2002, 30(2):155-160.
73. He K., Talaat R.E., Pool W.F., Reily M.D., Reed J.E., Bridges A.J., et al. Metabolic activation of troglitazone: identification of a reactive metabolite and mechanisms involved. Drug Metab Dispos 2004, 32(6):639-646.
74. Funk C., Ponelle C., Scheuermann G., Pantze M. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol Pharmacol 2001, 59(3):627-635.
75. Funk C., Pantze M., Jehle L., Ponelle C., Scheuermann G., Lazendic M., et al. Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate. Toxicology 2001, 167(1):83-98.
76. Yang K., Woodhead J.L., Watkins P.B., Howell B.A., Brouwer K.L.R. Systems pharmacology modeling predicts delayed presentation and species differences in bile acid-mediated troglitazone hepatotoxicity. Clin Pharmacol Ther 2014, 96(5):589-598.
77. Jemnitz K., Veres Z., Vereczkey L. Contribution of high basolateral bile salt efflux to the lack of hepatotoxicity in rat in response to drugs inducing cholestasis in human. Toxicol Sci 2010, 115(1):80-88.
78. Fattinger K., Funk C., Pantze M., Weber C., Reichen J., Stieger B., et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 2001, 69(4):223-231.
79. Leslie E.M., Watkins P.B., Kim R.B., Brouwer K.L. Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1)by bosentan: a mechanism for species differences in hepatotoxicity. J Pharmacol Exp Ther 2007, 321(3):1170-1178.
80. Woodhead J.L., Yang K., Siler S.Q., Watkins P.B., Brouwer K.L.R., Barton H.A., et al. Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury. Front Pharmacol 2014, 5:240.
81. Ito T., Ozaki Y., Son Y., Nishizawa T., Amuro H., Tanaka A., et al. Combined use of ursodeoxycholic acid and bosentan prevents liver toxicity caused by endothelin receptor antagonist bosentan monotherapy: two case reports. J Med Case Rep 2014, 8:250.
82. Hofmann A.F. Why bile acid glucuronidation is a minor pathway for conjugation of endogenous bile acids in man. Hepatology 2007, 45(4):1083-1084. [author reply 4-5].
83. Perreault M., Bialek A., Trottier J., Verreault M., Caron P., Milkiewicz P., et al. Role of glucuronidation for hepatic detoxification and urinary elimination of toxic bile acids during biliary obstruction. PLoS One 2013, 8(11):e80994.
84. Perreault M., Gauthier-Landry L., Trottier J., Verreault M., Caron P., Finel M., et al. The human UDP-glucuronosyltransferase UGT2A1 and UGT2A2 enzymes are highly active in bile acid glucuronidation. Drug Metab Dispos 2013, 41(9):1616-1620.
85. Dawson P.A., Karpen S.J. Intestinal transport and metabolism of bile acids. J Lipid Res 2015, 56(6):1085-1099.
86. Alnouti Y. Bile acid sulfation: a pathway of bile acid elimination and detoxification. Toxicol Sci 2009, 108(2):225-246.
87. Aleo M.D., Luo Y., Swiss R., Bonin P.D., Potter D.M., Will Y. Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump. Hepatology 2014, 60(3):1015-1022.
88. Rachek L.I., Yuzefovych L.V., Ledoux S.P., Julie N.L., Wilson G.L. Troglitazone, but not rosiglitazone, damages mitochondrial DNA and induces mitochondrial dysfunction and cell death in human hepatocytes. Toxicol Appl Pharmacol 2009, 240(3):348-354.
89. Allen K., Jaeschke H., Copple B.L. Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis. Am J Pathol 2011, 178(1):175-186.
90. Chen M., Borlak J., Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology 2013, 58(1):388-396.
91. Schadt S., Simon S., Kustermann S., Boess F., McGinnis C., Brink A., et al. Minimizing DILI risk in drug discovery - a screening tool for drug candidates. Toxicol In Vitro 2015, 30(1 Pt B):429-437.
92. Aubrecht J., Schomaker S.J., Amacher D.E. Emerging hepatotoxicity biomarkers and their potential to improve understanding and management of drug-induced liver injury. Genome Med 2013, 5(9):85.
93. Yamazaki M., Miyake M., Sato H., Masutomi N., Tsutsui N., Adam K.P., et al. Perturbation of bile acid homeostasis is an early pathogenesis event of drug induced liver injury in rats. Toxicol Appl Pharmacol 2013, 268(1):79-89.
94. Coen M., Lenz E.M., Nicholson J.K., Wilson I.D., Pognan F., Lindon J.C. An integrated metabonomic investigation of acetaminophen toxicity in the mouse using NMR spectroscopy. Chem Res Toxicol 2003, 16(3):295-303.
95. Coen M., Ruepp S.U., Lindon J.C., Nicholson J.K., Pognan F., Lenz E.M., et al. Integrated application of transcriptomics and metabonomics yields new insight into the toxicity due to paracetamol in the mouse. J Pharm Biomed Anal 2004, 35(1):93-105.
96. Sun J., Ando Y., Ahlbory-Dieker D., Schnackenberg L.K., Yang X., Greenhaw J., et al. Systems biology investigation to discover metabolic biomarkers of acetaminophen-induced hepatic injury using integrated transcriptomics and metabolomics. J Mol Biomark Diagn 2013, S1:002.
97. Luo L., Schomaker S., Houle C., Aubrecht J., Colangelo J.L. Evaluation of serum bile acid profiles as biomarkers of liver injury in rodents. Toxicol Sci 2014, 137(1):12-25.
98. Luo L., Kenny J., Warner R., Johnson K., Colangelo J.L. Profiling individual bile acids in human populations using a UPLC/MS/MS method [abstract]. Toxicol Suppl Toxicol Sci 2015, 144(1):256.
99. Beger R.D., Bhattacharyya S., Yang X., Gill P.S., Schnackenberg L.K., Sun J., et al. Translational biomarkers of acetaminophen-induced acute liver injury. Arch Toxicol 2015, 89(9):1497-1522.
100. Watanabe T., Miyake M., Shimizu T., Kamezawa M., Masutomi N., Shimura T., et al. Utility of bilirubins and bile acids as endogenous biomarkers for the inhibition of hepatic transporters. Drug Metab Dispos 2015, 43(4):459-466.
101. Weiler S., Merz M., Kullak-Ublick G.A. Drug-induced liver injury: the dawn of biomarkers?. F1000Prime Rep 2015, 7:34.